AstraZeneca Terminates Production of AtheroGenics' AGI-1067; Beats Pretax Estimates

|
Includes: AGIX, AZN
by: Jonathan Liss

AstraZeneca announced it would cease future development of AtheroGenics' experimental heart drug AGI-1067 after multiple clinical failures. The move will cost AstraZeneca $83 million and means AtheroGenics will reacquire all worldwide rights to AGI-1067, which it said it will continue to develop in a statement. Meanwhile, AstraZeneca reported an 11% increase in pretax profits during 1Q07 on a 13% rise in sales. Net pretax income was $2.27 billion, as the British pharmaceutical company reaped the benefits of a weaker dollar. Reuters consensus estimates called for pretax profits of $2.22 billion.

Sources: Press Release, Reuters, ShareCast, Briefing.com
Commentary: AstraZeneca to Buy MedImmune for $15.6 BillionAtheroGenics' Heart Drug Shows Promise on Secondary GoalsAtheroGenics' Uncertainty Continues, Will Remain for Some Timeazn agix
Stocks/ETFs to watch: AstraZeneca (NYSE:AZN), AtheroGenics (AGIX). Competitors: Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Bristol Myers Squibb (NYSE:BMY), Glaxosmithkline (NYSE:GSK), Eli Lilly (NYSE:LLY), Teva (NYSE:TEVA), Merck (NYSE:MRK), Schering-Plough (SGP), Sanofi-Aventis (NYSE:SNY). ETFs: iShares S&P Global Healthcare Sector (NYSEARCA:IXJ), Pharmaceutical HOLDRS (NYSEARCA:PPH), Vanguard Health Care ETF (NYSEARCA:VHT)

Seeking Alpha's news briefs are combined into a pre-market summary called Wall Street Breakfast. Get Wall Street Breakfast by email -- it's free and takes only seconds to sign up.